Capstone Investment Advisors
ACOR

Capstone Investment Advisors’s Acorda Therapeutics ACOR Stock Holding History

Capstone Investment Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-444
Closed -$39K – 1472
2020
Q2 		$39K Hold
444
– – ﹤0.01% 1287
2020
Q1 		$50K Sell
444
-75
-14% -$14.8K ﹤0.01% 1082
2019
Q4 		$127K Buy
519
+282
+119% +$71.2K ﹤0.01% 1292
2019
Q3 		$82K Buy
+237
New +$129K ﹤0.01% 1292

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Investment Advisors's ACOR Position: Q3 2020 in Review

Capstone Investment Advisors sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 444 shares — an estimated $39K sold.

Capstone Investment Advisors first reported a position in ACOR in Q3 2019 and held it in 4 quarters. The position peaked at $127K in Q4 2019. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • Capstone Investment Advisors reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Capstone Investment Advisors sold 444 Acorda Therapeutics shares in Q3 2020, an estimated $39K.
  • Capstone Investment Advisors first reported a position in Acorda Therapeutics in Q3 2019 and held it in 4 quarters.
  • Capstone Investment Advisors's Acorda Therapeutics position peaked at $127K in Q4 2019.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Capstone Investment Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.